Top

Published in:

Open Access 01-12-2012 | Review

Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients

Authors: H. W. Schroeder Jr., C. J. Dougherty

Published in: Infection | Issue 6/2012

Abstract

An available supply of intravenous immunoglobulin (IVIG) is essential for individuals with primary humoral immunodeficiency. A shortage in 1997 prompted the Food and Drug Administration (FDA) to revise guidelines for the licensure, production, and distribution of new IVIG products, including the standardization of United States clinical trials regarding endpoints for safety, efficacy, and pharmacokinetics. The following review is intended to present current information and results of clinical trials in patients with primary immunodeficiency treated with IVIG products currently licensed or awaiting licensure in the United States. The data presented are compiled from published clinical trials and prescribing information generated by manufacturers.

FDA Blood Products Advisory Committee 62nd Meeting, Bethesda, Maryland, March 26, 1999. Transcript, Miller Reporting Company, Inc. http://www.fda.gov/ohrms/dockets/ac/99/transcpt/3504t2.pdf.

FDA Blood Products Advisory Committee 65th Meeting, Silver Spring, Maryland, March 17, 2000 Transcript, Miller Reporting Company, Inc. http://www.fda.gov/ohrms/dockets/ac/00/transcripts/3603t2a.pdf.

FDA/CBER. Guidance for industry: safety, efficacy, and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency, 2005. http://www.fda.gov/OHRMS/DOCKETS/98fr/2005D-0438-gdl0001.pdf.

FDA/CBER. Guidance for industry: safety, efficacy, and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency, 2008. http://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/blood/ucm078526.pdf.

Behring EA, Kitasato S. Über das zustandekommen der Diphtherie-Immunität und der Tetanus-Immunität bei Thieren. Dtsch Med Wochenschr. 1890;16:1113–4.CrossRef

Gronski P, Seiler FR, Schwick HG. Discovery of antitoxins and development of antibody preparations for clinical uses from 1890 to 1990. Mol Immunol. 1991;28:1321–32.PubMedCrossRef

Schiff RI. Intravenous gammaglobulin: pharmacology, clinical uses and mechanisms of action. Pediatr Allergy Immunol. 1994;5:63–87.PubMedCrossRef

Cohn EJ, Strong LE, Hughes WL Jr, Mulford DJ, Ashworth JN, Melin M, Taylor HL. Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc. 1946;68:459–75.PubMedCrossRef

Oncley JL, Melin M, Richert DA, Cameron JW, Gross PM Jr. The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and beta-lipoprotein into subfractions of human plasma. J Am Chem Soc. 1949;71:541–50.PubMedCrossRef

10.

Bruton OC. Agammaglobulinema. Pediatrics. 1952;9:722–7.PubMed

11.

Janeway CA, Apt L, Gitlin D. Agammaglobulinemia. Trans Assoc Am Physicians. 1953;66:200–2.PubMed

12.

Janeway CA, Rosen FS. The gamma globulins. IV. Therapeutic uses of gamma globulin. N Engl J Med. 1966;275:826–31.PubMedCrossRef

13.

Barandun S, Kistler P, Jeunet F, Isliker H. Intravenous administration of human gamma-globulin. Vox Sang. 1962;7:157–74.PubMedCrossRef

14.

Pollack M. Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans. J Infect Dis. 1983;147:1090–8.PubMedCrossRef

15.

Bender S, Hetherington S. Haemophilus influenzae type b opsonins of intravenous immunoglobulins. J Clin Immunol. 1987;7:475–80.PubMedCrossRef

16.

Janeway CA, Merler E, Rosen FS, Salmon S, Crain JD. Intravenous gamma globulin. Metabolism of gamma globulin fragments in normal and agammaglobulinemic persons. N Engl J Med. 1968;278:919–23.PubMedCrossRef

17.

Hooper JA, Alpern M, Mankarious S. Immunoglobulin manufacturing procedures. In: Krijnen HW, Strengers PFW, van Aken WG, editors. Immunoglobulins. Amsterdam: Central Laboratory of the Netherlands Red Cross Blood Transfusion Service; 1988. p. 361–80.

18.

Nolte MT, Pirofsky B, Gerritz GA, Golding B. Intravenous immunoglobulin therapy for antibody deficiency. Clin Exp Immunol. 1979;36:237–43.PubMed

19.

Cunningham-Rundles C, Siegal FP, Smithwick EM, Lion-Boulé A, Cunningham-Rundles S, O’Malley J, Barandun S, Good RA. Efficacy of Intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann Intern Med. 1984;101:435–9.PubMed

20.

Ochs HD, Lee ML, Fischer SH, Kingdon HS, Wedgwood RJ. Efficacy of a new intravenous immunoglobulin preparation in primary immunodeficient patients. Clin Ther. 1987;9:512–22.PubMed

21.

Roifman CM, Gelfand EW. Replacement therapy with high dose intravenous gamma-globulin improves chronic sinopulmonary disease in patients with hypogammaglobulinemia. Pediatr Infect Dis J. 1988;7:S92–6.PubMedCrossRef

22.

Roifman CM, Schroeder H, Berger M, Sorensen R, Ballow M, Buckley RH, Gewurz A, Korenblat P, Sussman G, Lemm G. Comparison of the efficacy of IGIV-C, 10 % (caprylate/chromatography) and IGIV-SD, 10 % as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int Immunopharmacol. 2003;3:1325–33.PubMedCrossRef

23.

Ballow M, Berger M, Bonilla FA, Buckley RH, Cunningham-Rundles CH, Fireman P, Kaliner M, Ochs HD, Skoda-Smith S, Sweetser MT, Taki H, Lathia C. Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%). Vox Sang. 2003;84:202–10.PubMedCrossRef

24.

Ochs HD, Pinciaro PJ; Octagam Study Group. Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases. J Clin Immunol. 2004;24:309–14.PubMedCrossRef

25.

Church JA, Leibl H, Stein MR, Melamed IR, Rubinstein A, Schneider LC, Wasserman RL, Pavlova BG, Birthistle K, Mancini M, Fritsch S, Patrone L, Moore-Perry K, Ehrlich HJ; US-PID-IGIV 10% -Study Group10. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. J Clin Immunol. 2006;26:388–95.PubMedCrossRef

26.

Baxter Healthcare Corporation. Gammagard Liquid [Immune Globulin Infusion (Human)] 10% prescribing information, 2009. http://www.baxter.com/products/biopharmaceuticals/downloads/gamliquid_PI.pdf

27.

Berger M; Flebogamma 5% DIF Investigators. A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma 5% DIF, the next generation of Flebogamma. J Clin Immunol. 2007;27:628–33.PubMedCrossRef

28.

Grifols Biologicals. Flebogamma 5% DIF [Immune Globulin Intravenous (Human)] prescribing information, 2006. http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM172599.pdf.

29.

Stein MR, Nelson RP, Church JA, Wasserman RL, Borte M, Vermylen C, Bichler J; IgPro10 in PID study group. Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J Clin Immunol. 2009;29:137–44.PubMedCrossRef

30.

CSL Behring AG. Privigen, Immune Globulin Intravenous (Human), 10% Liquid prescribing information, 2009. http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM303092.pdf.

31.

Berger M, Pinciaro PJ, Althaus A, Ballow M, Chouksey A, Moy J, Ochs H, Stein M. Efficacy, pharmacokinetics, safety, and tolerability of flebogamma 10% DIF, a high-purity human intravenous immunoglobulin, in primary immunodeficiency. J Clin Immunol. 2010;30:321–9.PubMedCrossRef

32.

Grifols Biologicals. Flebogamma 10% DIF, Immune Globulin Intravenous (Human), 10% Liquid prescribing information, 2010. http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM221606.pdf.

33.

Moy JN, Scharenberg AM, Stein MR, Suez D, Roberts RL, Levy RJ, Ballow M, Fasano MB, Dash CH, Leach SJ. Efficacy and safety of a new immunoglobulin G product, Gammaplex(^®), in primary immunodeficiency diseases. Clin Exp Immunol. 2010;162:510–5.PubMedCrossRef

34.

BioProducts Laboratory. Gammaplex, Immune Globulin Intravenous (Human), 5% Liquid prescribing information, 2009. http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM182963.pdf

35.

Wasserman RL, Church JA, Stein M, Moy J, White M, Strausbaugh S, Schroeder H, Ballow M, Harris J, Melamed I, Elkayam D, Lumry W, Suez D, Rehman SM. Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency. J Clin Immunol. 2012;32:663–9.PubMedCrossRef

Title: Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients
Authors: H. W. Schroeder Jr.
C. J. Dougherty
Publication date: 01-12-2012
Publisher: Springer-Verlag
Published in: Infection / Issue 6/2012
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI: https://doi.org/10.1007/s15010-012-0323-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2012

Aseptic meningitis and adult respiratory distress syndrome caused by Borrelia persica

Lack of benefit of preoperative antimicrobial prophylaxis in children with acute appendicitis: a prospective cohort study

Impact of surgical site infections after open and laparoscopic colon and rectal surgeries on postoperative resource consumption

Four cases of possible human infections with Delftia lacustris

Purpura fulminans in a child due to Neisseria meningitidis

Pulmonary coccidiomycosis in New Delhi, India

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page